Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: Extrapolation of data to clinical practice

JAMA Ophthalmology

Volumn 134, Issue 1, 2016, Pages 95-99

  Heier, Jeffrey S ^a   Bressler, Neil M ^b,c   Avery, Robert L ^d   Bakri, Sophie J ^e   Boyer, David S ^f   Brown, David M ^g   Dugel, Pravin U ^f,h   Freund, K Bailey ⁱ   Glassman, Adam R ^j   Kim, Judy E ^k   Martin, Daniel F ^l   Pollack, John S ^m,n   Regillo, Carl D ^o,p   Rosenfeld, Philip J ^q   Schachat, Andrew P ^l   Wells, John A ^r  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JAMA   (United States)

^d California Retina Consultants   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h RETINAL CONSULTANTS OF ARIZONA   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j JAEB CENTER FOR HEALTH RESEARCH   (United States)

^k MEDICAL COLLEGE OF WISCONSIN   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m Illinois Retina Associates   (United States)

ⁿ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^o WILLS EYE HOSPITAL   (United States)

^p THOMAS JEFFERSON UNIVERSITY   (United States)

^q UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^r Palmetto Retina Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

CATARACT; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DIABETIC MACULAR EDEMA; DRUG COST; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; HUMAN; LASER COAGULATION; PATIENT CARE; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA TEAR; REVIEW; VISUAL ACUITY; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIABETIC RETINOPATHY; DRUG EFFECTS; DRUG FORMULATION; ECONOMICS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; DRUG COMPOUNDING; DRUG COSTS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84958554696     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.4110     Document Type: Review

References (7)

1. Wells JA, Glassman AR, Ayala AR, et al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
2. Avery R, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34:S1-S18.
3. Jampol LM, Glassman AR, Bressler NM. Comparative effectiveness trial for diabetic macular edema: three comparisons for the price of 1 study from the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol. 2015;133(9):983-984.
4. Elman MJ, Aiello LP, Beck RW, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077.e35. doi:10.1016/j.ophtha.2010.02.031.
5. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol. Am J Ophthalmol. 2003;135(2):194-205.
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
7. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4): 789-801.